Intelligence Profile
Safety Profile
The safety evidence for tesofensine is limited, derived primarily from small clinical trials and preclinical studies. Available data suggests several important safety considerations.
Known Side Effects
Cardiovascular Effects: The most significant safety concern appears to be cardiovascular impact. Clinical trials specifically examined tesofensine's effects on heart rate, with one dedicated Phase 1 study investigating its interaction with metoprolol on 24-hour mean heart rate. The need for concurrent metoprolol administration in multiple trials (including a 48-week safety study in hypothalamic obesity patients) suggests tesofensine may cause clinically meaningful increases in heart rate or blood pressure, though specific adverse event rates are not available from the provided evidence.
Other Potential Effects: Preclinical studies indicate tesofensine affects GABAergic neurons in the hypothalamus and may cause sex-specific effects on stereotypic behaviors in animal models. However, the clinical relevance of these findings in humans remains unclear.
Contraindications and Special Populations
Evidence is extremely thin regarding specific contraindications. Based on the cardiovascular concerns suggested by the clinical trial designs, patients with pre-existing cardiovascular disease would likely need careful evaluation, though explicit contraindications are not established in the available evidence.
The safety profile in specific populations including pregnant women, children, elderly patients, and those with hepatic or renal impairment has not been adequately characterized in the provided studies.
Drug Interactions
Limited evidence suggests potential interactions with cardiovascular medications, as multiple trials combined tesofensine with metoprolol. However, comprehensive drug interaction data is not available from the provided evidence. As a triple reuptake inhibitor, tesofensine would theoretically have potential for interactions with other medications affecting neurotransmitter systems, but specific interactions have not been well-studied.
Important Limitations
The safety database for tesofensine appears limited. Most completed trials were Phase 1 or Phase 2 studies, suggesting limited exposure data in humans. Long-term safety data beyond 48 weeks is not available from the provided evidence. The specific adverse event profiles, discontinuation rates, and serious adverse events are not detailed in the available study information.
Disclaimer: This information is for educational purposes only and does not constitute medical advice. Patients should consult healthcare providers for personalized medical guidance regarding tesofensine or any medication.